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S208 Poster Session Imorning on collection one hour prior to the collection time. All
patients received 0.24mg/kg/day of Plerixafor. There were no side
effects observed. Only one of the patients required a second dose
of Plerixafor and five patients had not reach the required CD34
count of 4  106 cells/kg.
Conclusions: Plerixafor was used at The London Clinic recently
with favourable outcomes. The target for all cases was CD341 cells
4  106 cells/kg recipient body weight. Two patients responded ex-
tremely well with a CD341 count of 21.79  106 cells/kg and 15.16
 106 cells/kg achieved. Three patients had a poor outcomes, where
the collection was below 3  106 cells/kg of CD341 count was col-
lected. The other seven patients met the target required of CD341
count of 4  106 cells/kg or above.
According to this study Plerixafor has improved PBSC outcome
with seven patients out of 12 in this study.
Due to the small numbers this study it is thus far inconclusive but
it would be sensible to say Prelixafor made a difference for our 11 pa-
tients. An Ongoing study with new patient experiences is needed.
More than one dose of Plerixafor was required for heavily pre-treated
patients who are historically poor mobiliser of PBSC.147
ANALYSIS OF TOXICITY PROFILE OF CBV VS BEAM IN LYMPHOMA
PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANT – A SINGLE
INSTITUTION RETROSPECTIVE REVIEW
Khalife, M., Neme, K., Janakiraman, N. Henry Ford Hospital, Detroit,
MI
Introduction: Several preparative regimens are used in Hodgkin
lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients prior
to autologous hematopoietic stem cell transplant (HSCT). These in-
clude CBV (cylophosphamide, etoposide and carmustine), BEAM
(carmustine, etoposide, cytarabine andmelphalan) or TBI based reg-
imens. This study retrospectively compares the toxicities of CBV vs
BEAM in lymphoma post-HSCT in our institution.
Methods: We retrospectively reviewed the charts of 77 lymphoma
patients who underwent autologous HSCT between 1999 and
2010. 35 patients received CBV between 1999 and 2005 (11 HL
and 24 NHL) and 42 patients received BEAM between 1999 and
2010 (12 HL and 30 NHL). CBV consisted of cyclophosphamide
7200 mg/m2, etoposide 1600 mg/m2, and carmustine 300 mg/m2.
BEAM consisted of carmustine 300 mg/m2, etoposide 1600 mg/
m2, cytarabine 1600 mg/m2, and melphalan 140 mg/m2. Lung toxic-
ity was defined as a 15% drop in adjusted DLCO (carbon monoxide
diffusing capacity) on pulmonary function test (PFT) or respiratory
symptoms requiring steroids within six weeks post-HSCT. Clini-
cally significant lung toxicity was defined as respiratory symptoms
requiring steroids or leading to death.
Results: Lung toxicity occurred in 10/42 (23.8%) of BEAM and
13/35 (37.1%) of CBV patients (p 5 0.203). However, clinically
significant lung toxicity occurred only in 3/42 (7.1%) of BEAM
(one of which was lethal) and only in 1/35 (2.9%) of CBV patients
(p 5 0.621). All 4 clinically significant lung toxicities occurred in
HL. Cardiac toxicities were comparable (11.9% after BEAM vs
8.6% after CBV; p 5 0.722). Time to engraftment defined as
neutrophil . 500 (12.9 days after CBV vs 11.3 days after
BEAM; p 5 0.031), diarrhea (65.7% after CBV vs 31.0% after
BEAM; p 5 0.002) and infections requiring intravenous antibi-
otics (60.0% after CBV vs 14.3% after BEAM; p\ 0.001) were
higher after CBV. Severe mucositis requiring parenteral nutrition
was comparable (21.4% after BEAM and 14.3 after CBV p 5
0.418).
Conclusion: HL patients, especially those who received BEAM,
appear to be at higher risk of clinically significant lung toxicity
compared to NHL patients. Prior bleomycin may have contrib-
uted to this. Most patients who had a 15% decline in DLCO
post HSCT did not experience clinically significant lung toxicity.
Therefore, the value of post HSCT PFT is unclear and close
monitoring of high risk patients for symptoms is warranted.
Finally, the time to engraftment and other toxicities favored
BEAM.148
G-CSF DOSE ESCALATION STARTING DAY 8 AFTER SALVAGE RICE
CHEMOTHERAPY RESULTS IN ADEQUATE AND PREDICTABLE AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL COLLECTION IN RELAPSED/
REFRACTORY LYMPHOMA
Weber, A.M., Pillai, P., Styler, M.J., Mullaney, R., Topolsky, D.,
Ward, K.M., Crilley, P. Hahnemann University Hospital, Philadelphia,
PA
Introduction: Optimal dosing and timing of G-CSF for stem cell
mobilization after salvage RICE (Rituximab, Ifosfamide, Carbopla-
tin, and Etoposide) for relapsed/refractory lymphoma is unclear.
Common G-CSF regimens have doses ranging from 5-16 mcg/kg/
d starting one to several days after chemotherapy until a predeter-
mined variable is reached to initiate peripheral blood stem cell
collection.
Patients and Methods: We performed a retrospective analysis of
stem cell collection with G-CSF after salvage RICE for consecutive
patients with relapsed/refractory lymphoma at our center. Our earlier
practice was augmenting stem cell mobilization with 16 mcg/kg/
d G-CSF from Day 1 to final day of collection to achieve WBC .
10,000/mm3 prior to initiating stem collection (Standard dose group).
We observed difficulties in terms of adequacy and timing of collection
with this method. We modified the regimen to G-CSF at 5 mcg/kg/
d from Day 1 to 7, followed by dose escalation to 16 mcg/kg/d on
Day 8 until final day of collection, and a planned peripheral blood
stem collection beginning Day 12 (Dose escalation group).
Results: Standard dose group: Three patients (2 DLBCL, 1 Hodg-
kin’s lymphoma) received salvage RICE for 2 to 3 cycles. Peripheral
blood stem cell collection resulted in CD341 yields of only 0.3 to 3.0
x106 per kg in 5 to 6 apheresis sessions initiated between day 11 and
day 16.
Dose escalation group: Four patients (2 DLBCL, 1 T cell rich B
cell lymphoma, 1 Hodgkin’s lymphoma) received salvage RICE for
2 to 4 cycles. Peripheral blood stem cell collection resulted in
more than sufficient CD341 yields (all . 3x106 per kg, range 3.80
to 7.10 x106) in only 1 to 3 apheresis sessions initiated on day 12.
Conclusion: A timed escalation to high dose G-CSF on day 8 sal-
vage RICE chemotherapy for relapsed/refractory lymphoma re-
sulted in superior CD341 cells for collection with fewer apheresis
requirements and a predictable apheresis start day.149
OPTIMIZING THE EFFICACY OF PLERIXAFOR AS A SALVAGE OPTION
IN POOR MOBILIZERS FOLLOWING CHEMOTHERAPY PLUS G-CSF
MOBILIZATION
Kochuparambil, S.T.1, Mebel, E.R.3, DeRemer, D.L.2, Jillella, A.P.1,
Awan, F.T.1 1Medical College of Georgia, Augusta, GA; 2Medical College
of Georgia, Augusta, GA; 3University of PittsburghMedical Center, Pitts-
burgh, PA
Introduction: Recent data of the combination of G-CSF (G) with
Plerixafor (P) has established its efficacy in stem cell mobilization
for autologous transplants. However, there is limited data about
the utility of plerixafor in patients who are beingmobilized with che-
motherapy and G.
Methods: In this study we describe our experience with the use of
plerixafor as a salvage option in 12 patients (6 Non-Hodgkin Lym-
phoma, 3 Multiple Myeloma, 2 Hodgkin Lymphoma, 1 Ewings
Sarcoma) who fail to optimally mobilize CD341 cells (\ 10
CD341 cells/ul at neutrophil recovery) after G. Patients received
Cyclophosphamide (CY) (3-4 g/m2) followed by G (10 mcg/kg)
from D1 to D10. Data was collected on mobilization and transplant
outcomes and analyzed utilizing SPSS version 13.0.
Results: The median age was 60 years (range 18-76). 75% were
males. Patients had received a median of 2 lines of therapy (range
1-3) prior to stem cell mobilization. Following failure to mobilize
with G post CY, at neutrophil recovery patients received a median
of 2.5 doses of P (range 1-8). The average number of apheresis ses-
sions was 4.2 and the total number of CD341 stem cells collected
was 4.0x106/kg. Utilizing a cut-off of 2x106 CD341/kg, one patient
who received P had an unsuccessful harvest. ThreeNHLpatients re-
quired. 4 doses of P, but all eventually collected. 2 106 CD341
Poster Session I S209cells/kg. The mean peripheral CD34 count prior to the use of P was
3.3/ul, and increased to 8.8/ul after its use.
Conclusion: Our limited single-center outcomes data suggests that
the addition of P as a salvage agent may improve mobilization out-
comes in poor mobilizers. Further evaluation is needed to combine
P with CY1G in terms of optimal timing and dosing of chemother-
apy utilized.150
SUCCESSFUL AUTOLOGOUS STEM CELL TRANSPLANT AFTER 21 YEARS
OF CRYOPRESERVATION
Cherry, M.A.1, Kern, W.2, Wageman, B.2, Epstein, R.1, O’neal, C.1,
Kratochvill, K.2, Selby, G.1, Holter, J.1 1OklahomaUniversity Health Sci-
ences Center, Oklahoma City, OK; 2Oklahoma University Health Sciences
Center, Oklahoma City, OK
Introduction: Successful transplantation of cryopreserved hemato-
poietic stem cells can be regularly achieved provided sufficient num-
bers of cells are administered. The duration of hematopoietic stem
cell viability is unclear. Evidence of autologous repopulation has
been seen at 14 years after bone marrow transplant and 12 years after
peripheral stem cell transplant. We report a successful autologus
transplantation 21 y after cryopreservation.
Case: The patient is 43 year old man found to have follicular lym-
phoma with bone marrow involvement in 1989 at age 22. He
achieved complete remission after treatment with two cycles of
Chorambucil. Bone marrow (BM) procurement and cryopreserva-
tion was performed at that time for possible subsequent infusion.
The procured BM consisted of a total cell count of 1.21  108
cells/per kg body weight with a total volume of 354 ml. Equal parts
of 20%DMSOwere combined with marrow to a final concentration
of 10% DMSO. The BM was stored in the liquid phase of nitrogen
until date of infusion 21 years later. Our patient relapsed in 1996, and
underwent treatment in 2006 with six cycles of Fludarabine and Rit-
uximab, achieving a complete remission. He continued Rituximab
maintenance and then developped pancytopenia. Work-up con-
firmed MDS with 5q- and t(6q21;17p13) in 20/20 cells by karyotype
analysis. Assessment of previously cryopreserved marrow was under-
taken showing no evidence of cytogenetic or histological changes.
The patient was prepared with Busulfan IV at 0.8/kg q 6 hours 
4 days and Cyclophosphamide 60mg/kg IV  2 days. The BM was
infused and samples from the infused marrow showed 65-75% via-
bility by Tryptan blue assay. White cell engraftment occurred on
day 17 and platelet reached 20,000/uL by day 30.
Follow-up 2months post transplant revealedWBCof 2.6 x103/uL
with ANC 1.5103/uL, Hgb 9.8 gr/dl and platelets of 43,000/uL.
FISH analysis for 5q performed showed 85/200 cells positive for
5q-. BM biopsy confirmed dysplastic features consistent with his
pre-transplant BM.
Our case illustrates that even in the setting of marginal numbers of
infused marrow components and after prolonged cryopreservation,
repopulation can readily occur. To our knowledge, this is the oldest
successful cryopreserved autologous bone transplant at 21 years post
preservation. As novel uses of stem cells advance, optimal storage of
various cellular components is necessary. This should be further
investigated on a larger scale in the future.CLINICAL CELLULAR THERAPY151
TUMOR-INFILTRATING LYMPHOCYTES ARE PRESENT IN CANCER
RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (ALLOHSCT), OF DONOR ORIGIN, DISTINCT FROM PERIPHERAL
BLOOD DONOR LYMPHOCYTES AND EXHIBIT EFFECTOR FUNCTION
WITH CD3/CD28 COSTIMULATION EX-VIVO
Hardy, N.M., Hakim, F.T., Fellowes, V.S., Rose, J.J., Gress, R.E.,
Bishop, M.R. National Cancer Institute, Bethesda, MD
We theorized that in patients with persistent or relapsed cancer
following alloHSCT, tumor would be a source of tumor-reactivedonor T lymphocytes that could be expanded ex vivo to provide
a potent T cell therapy.We recently reported our initial clinical re-
sults demonstrating feasibility, safety and biologic activity of this
approach in patients with refractory B cell tumor relapse after al-
loHSCT (ASH 2010). We report here the characterization of the
initial tumor infiltrate as compared to circulating T cell popula-
tions, and as compared to expanded products from tumor and
blood. We determined that tumor-infiltrating donor T cells (con-
firmed by chimerism assays) differed from peripheral donor T cell
populations in individual patients in terms of T cell frequency,
na€ıve/memory phenotype, ratio of CD4:CD8 cells and frequencies
of effector and regulatory T cell populations. Following a-CD3/
CD28 antibody-coated bead expansion with low dose IL-2,
PCR-based chimerism assessment of products demonstrated that
the costimulated lymphocytes were of donor origin; by flow, prod-
ucts were greater than 95% CD31 T cells. CD41 T cells usually
predominated, but there was significant patient variation in expan-
sions from both tumor infiltrates and blood. Both expanded tumor
and blood products demonstrated increased expression of markers
of activation and effector function (CD4: CD40L; CD8: CD137,
perforin, NKG2D). The proportion of FoxP31 Treg cells de-
clined and IFN-producing TBet1 Th1/Tc1 effectors became the
dominant T cell population. While the percentage of cells express-
ing CD27 and CD28 declined proportionate to the duration of cul-
ture, their expression was retained in a significant proportion of
cells after our typical 12-day culture. Our findings support the hy-
pothesis that, after allotransplant, donor lymphocytes can be iden-
tified in residual/progressing tumor, and appear to be distinct from
circulating T cell populations. Furthermore, these tumor-infiltrat-
ing T cells can be effectively expanded, even from minor popula-
tions, to become T-Bet1 T effectors, plausibly circumventing
a mechanism of GVL resistance. Costimulated tumor-derived do-
nor lymphocytes may be a therapeutic option for patients without
a source of, or who have not responded to, donor lymphocyte in-
fusion for disease progression after alloHSCT.152
NON-EXPANDED PR1-SPECIFIC CTL SORT-PURIFIED DIRECTLY FROM
CORD BLOOD LYMPHOCYTES DEPLETE HUMAN AML IN VIVO
St. John, L.S., He, H., Quintanilla, K., Ma, Q., Shpall, E.J.,
Alatrash, G., Clise-Dwyer, K., Molldrem, J.J. The University of Texas
M.D. Anderson Cancer Center, Houston, TX
Relapse remains a significant problem following allogeneic stem
cell transplantation (SCT) for AML. Adoptive transfer of leukemia-
specific cytotoxic T lymphocytes (CTL), such as PR1-specific
CTL, might be used to treat persistent leukemia after SCT by en-
hancing graft versus leukemia (GVL) while minimizing graft versus
host disease (GVHD).A limitationof this approach is the limitedper-
sistence of adoptively transferred T cells in the recipient, due in part
to the lengthy ex vivo expansion of low frequency cells necessary to
obtain a sufficient cell number.We chose to study PR1-CTLderived
fromumbilical cord blood (UCB)based onour observation thatUCB
PR1-CTL are increased 100- to 1,000-fold compared to adult pe-
ripheral blood (PB), suggesting UCB might be a rich source of
PR1-CTL. Because UCB is associated with a decreased risk of
GVHD, in part because of the predominance of naive T cells, it
may also be a preferred platform to transfer GVL with minimal risk
of GVHD. We found the frequency of PR1-CTL in UCB to be
0.007 to 0.345% (mean 0.117%; n 5 57) of CD81 cells compared
with a frequency of\0.001% in healthy adult PB. Therefore, we hy-
pothesized that a sufficient number of PR1-CTL fromUCBcould be
obtained by PR1/HLA-A2 tetramer-based cell sorting and infused
without further expansion to mediate GVL. To test this, CD81 T
cells fromHLA-A21UCB units were first enriched via whole blood
negative immunodensity separation. Enriched cells were sorted (.
98% purity) into PR1-CTL and PR1-CTL-depleted CD81 cells
(PDC) and briefly activated ex vivo for 48 hours with soluble anti-
CD3/anti-CD281 IL-2.After 48 hours, PR1-CTLspecifically lysed
PR1-pulsed T2 cells although 95% of PR1-CTL and PDC retained
a CCR71CD45RA1 naive phenotype. Next, 1  104 cells were in-
fused into NOD/SCIDmice engrafted for 7 days with 2-4 106 hu-
man AML blasts. Three separate experiments were performed. Two
